CAMBRIDGE, Mass.--(BUSINESS WIRE)--Hydra Biosciences, a leader in the field of Transient Receptor Potential (TRP) channel modulation, today announced its newly formed pain medical advisory board (MAB) with the appointments of three leading physicians and scientists, Dr. Robert Dworkin, Dr. Roy Freeman and Dr. Nathaniel Katz. Dr. Paul Goldenheim, member of the Hydra Biosciences Board of Directors and Hydra founder, Dr. David Clapham, chair of the Hydra Scientific Advisory Board, also have seats on the MAB, which will provide clinical and scientific guidance as Hydra continues to develop HX-100, its clinical stage TRPA1 antagonist, in painful diabetic neuropathy.
Help employers find you! Check out all the jobs and post your resume.
